Inoue Takahiro, Ogawa Osamu
Department of Urology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Prostate Cancer. 2011;2011:647987. doi: 10.1155/2011/647987. Epub 2011 Oct 5.
Almost all patients who succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the standard treatment for this disease and is associated with modest prolongation of survival, there is an urgent need for novel treatments for castration-resistant prostate cancer (CRPC). Great advances in our understanding of the biological and molecular mechanisms of prostate cancer progression have resulted in many clinical trials of numerous targeted therapies. In this paper, we review mechanisms of CRPC development, with particular focus on recent advances in the understanding of specific intracellular signaling pathways participating in the proliferation of CRPC cells.
几乎所有死于前列腺癌的患者都是因转移性去势抵抗性疾病而死亡。虽然多西他赛是这种疾病的标准治疗方法，且与生存期的适度延长相关，但对于去势抵抗性前列腺癌（CRPC）来说，迫切需要新的治疗方法。我们对前列腺癌进展的生物学和分子机制的理解取得了巨大进展，这导致了众多靶向治疗的临床试验。在本文中，我们回顾了CRPC发展的机制，特别关注在参与CRPC细胞增殖的特定细胞内信号通路理解方面的最新进展。
